Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Using Resistin, glucose, age and BMI to predict the presence of breast cancer

Authors: Miguel Patrício, José Pereira, Joana Crisóstomo, Paulo Matafome, Manuel Gomes, Raquel Seiça, Francisco Caramelo

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

The goal of this exploratory study was to develop and assess a prediction model which can potentially be used as a biomarker of breast cancer, based on anthropometric data and parameters which can be gathered in routine blood analysis.

Methods

For each of the 166 participants several clinical features were observed or measured, including age, BMI, Glucose, Insulin, HOMA, Leptin, Adiponectin, Resistin and MCP-1. Machine learning algorithms (logistic regression, random forests, support vector machines) were implemented taking in as predictors different numbers of variables. The resulting models were assessed with a Monte Carlo Cross-Validation approach to determine 95% confidence intervals for the sensitivity, specificity and AUC of the models.

Results

Support vector machines models using Glucose, Resistin, Age and BMI as predictors allowed predicting the presence of breast cancer in women with sensitivity ranging between 82 and 88% and specificity ranging between 85 and 90%. The 95% confidence interval for the AUC was [0.87, 0.91].

Conclusions

These findings provide promising evidence that models combining age, BMI and metabolic parameters may be a powerful tool for a cheap and effective biomarker of breast cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Crisóstomo J, et al. Hyperresistinemia and metabolic dysregulation: the close crosstalk in obese breast cancer. Endocrine. 2016;53(2):433-42. Crisóstomo J, et al. Hyperresistinemia and metabolic dysregulation: the close crosstalk in obese breast cancer. Endocrine. 2016;53(2):433-42.
2.
go back to reference Cole KD, He HJ, Wang L. Breast cancer biomarker measurements and standards. Proteomics Clin Appl. 2013;7(1–2):17–29.CrossRefPubMed Cole KD, He HJ, Wang L. Breast cancer biomarker measurements and standards. Proteomics Clin Appl. 2013;7(1–2):17–29.CrossRefPubMed
3.
go back to reference Hwa HL, et al. Prediction of breast cancer and lymph node metastatic status with tumour markers using logistic regression models. J Eval Clin Pract. 2008;14(2):275–80.CrossRefPubMed Hwa HL, et al. Prediction of breast cancer and lymph node metastatic status with tumour markers using logistic regression models. J Eval Clin Pract. 2008;14(2):275–80.CrossRefPubMed
4.
go back to reference Santillan-Benitez JG, et al. The tetrad BMI, Leptin, Leptin/Adiponectin (L/a) ratio and CA 15-3 are reliable biomarkers of breast cancer. J Clin Lab Anal. 2013;27(1):12–20.CrossRefPubMed Santillan-Benitez JG, et al. The tetrad BMI, Leptin, Leptin/Adiponectin (L/a) ratio and CA 15-3 are reliable biomarkers of breast cancer. J Clin Lab Anal. 2013;27(1):12–20.CrossRefPubMed
5.
go back to reference Dalamaga M, et al. Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clin Biochem. 2013;46(7–8):584–90.CrossRefPubMed Dalamaga M, et al. Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clin Biochem. 2013;46(7–8):584–90.CrossRefPubMed
6.
go back to reference Assiri AM, Kamel HF. Evaluation of diagnostic and predictive value of serum adipokines: Leptin, resistin and visfatin in postmenopausal breast cancer. Obes Res Clin Pract. 2015;10(4):442-53. Assiri AM, Kamel HF. Evaluation of diagnostic and predictive value of serum adipokines: Leptin, resistin and visfatin in postmenopausal breast cancer. Obes Res Clin Pract. 2015;10(4):442-53.
7.
go back to reference Patrício, M. and F. Caramelo, Comment on "evaluation of diagnostic and predictive value of serum adipokines: Leptin, resistin and vistafin in postmenopausal breast cancer". Obesity Research & Clinical Practice, 2016. Patrício, M. and F. Caramelo, Comment on "evaluation of diagnostic and predictive value of serum adipokines: Leptin, resistin and vistafin in postmenopausal breast cancer". Obesity Research & Clinical Practice, 2016.
8.
go back to reference Provatopoulou X, et al. Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics. BMC Cancer. 2015;15(1):898.CrossRefPubMedPubMedCentral Provatopoulou X, et al. Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics. BMC Cancer. 2015;15(1):898.CrossRefPubMedPubMedCentral
9.
go back to reference Witten, I.H., E. Frank, and M.A. Hall, Data Mining: Practical Machine Learning Tools and Techniques. 3rd ed. Morgan Kaufmann; 2011. Witten, I.H., E. Frank, and M.A. Hall, Data Mining: Practical Machine Learning Tools and Techniques. 3rd ed. Morgan Kaufmann; 2011.
10.
go back to reference Kloten V, et al. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res. 2013;15(1):R4.CrossRefPubMedPubMedCentral Kloten V, et al. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res. 2013;15(1):R4.CrossRefPubMedPubMedCentral
11.
go back to reference Opstal-van Winden AW, et al. A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum. Int J Mol Sci. 2012;13(10):13587–604.CrossRefPubMedPubMedCentral Opstal-van Winden AW, et al. A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum. Int J Mol Sci. 2012;13(10):13587–604.CrossRefPubMedPubMedCentral
12.
go back to reference Zhu Q, et al. Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria. Breast Cancer Res. 2014;16(5):456.CrossRefPubMedPubMedCentral Zhu Q, et al. Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria. Breast Cancer Res. 2014;16(5):456.CrossRefPubMedPubMedCentral
13.
go back to reference Chlebowski RT, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst. 2007;99(22):1695–705.CrossRefPubMed Chlebowski RT, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst. 2007;99(22):1695–705.CrossRefPubMed
14.
go back to reference Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111–30.CrossRefPubMed Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111–30.CrossRefPubMed
15.
go back to reference Khakpour G, et al. DNA methylation as a promising landscape: a simple blood test for breast cancer prediction. Tumour Biol. 2015;36(7):4905–12.CrossRefPubMed Khakpour G, et al. DNA methylation as a promising landscape: a simple blood test for breast cancer prediction. Tumour Biol. 2015;36(7):4905–12.CrossRefPubMed
16.
go back to reference Zheng BC, Yoon SW, Lam SS. Breast cancer diagnosis based on feature extraction using a hybrid of K-means and support vector machine algorithms. Expert Syst Appl. 2014;41(4):1476–82.CrossRef Zheng BC, Yoon SW, Lam SS. Breast cancer diagnosis based on feature extraction using a hybrid of K-means and support vector machine algorithms. Expert Syst Appl. 2014;41(4):1476–82.CrossRef
17.
go back to reference Maglogiannis I, Zafiropoulos E, Anagnostopoulos I. An intelligent system for automated breast cancer diagnosis and prognosis using SVM based classifiers. Appl Intell. 2009;30(1):24–36.CrossRef Maglogiannis I, Zafiropoulos E, Anagnostopoulos I. An intelligent system for automated breast cancer diagnosis and prognosis using SVM based classifiers. Appl Intell. 2009;30(1):24–36.CrossRef
18.
go back to reference Aličković E, Subasi A. Breast cancer diagnosis using GA feature selection and rotation Forest. Neural Comput & Applic. 2017;28(4):753–63. Aličković E, Subasi A. Breast cancer diagnosis using GA feature selection and rotation Forest. Neural Comput & Applic. 2017;28(4):753–63.
19.
go back to reference Wolberg WH, Mangasarian OL. Multisurface method of pattern separation for medical diagnosis applied to breast cytology. Proc Natl Acad Sci U S A. 1990;87(23):9193–6.CrossRefPubMedPubMedCentral Wolberg WH, Mangasarian OL. Multisurface method of pattern separation for medical diagnosis applied to breast cytology. Proc Natl Acad Sci U S A. 1990;87(23):9193–6.CrossRefPubMedPubMedCentral
20.
go back to reference Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 2007;96(5):644–7.CrossRefPubMed Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 2007;96(5):644–7.CrossRefPubMed
22.
go back to reference Gromski PS, et al. A comparative investigation of modern feature selection and classification approaches for the analysis of mass spectrometry data. Anal Chim Acta. 2014;829:1–8.CrossRefPubMed Gromski PS, et al. A comparative investigation of modern feature selection and classification approaches for the analysis of mass spectrometry data. Anal Chim Acta. 2014;829:1–8.CrossRefPubMed
23.
go back to reference Xu QS, Liang YZ. Monte Carlo cross validation. Chemom Intell Lab Syst. 2001;56(1):1–11.CrossRef Xu QS, Liang YZ. Monte Carlo cross validation. Chemom Intell Lab Syst. 2001;56(1):1–11.CrossRef
24.
go back to reference Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005;365(9458):488–92.CrossRefPubMed Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005;365(9458):488–92.CrossRefPubMed
25.
go back to reference van der Ploeg T, Austin PC, Steyerberg EW. Modern modelling techniques are data hungry: a simulation study for predicting dichotomous endpoints. BMC Med Res Methodol. 2014;14:137.CrossRefPubMedPubMedCentral van der Ploeg T, Austin PC, Steyerberg EW. Modern modelling techniques are data hungry: a simulation study for predicting dichotomous endpoints. BMC Med Res Methodol. 2014;14:137.CrossRefPubMedPubMedCentral
26.
go back to reference Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, Conant EF, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 2005;353:17.CrossRef Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, Conant EF, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 2005;353:17.CrossRef
27.
go back to reference Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35(29):1925–31.CrossRefPubMedPubMedCentral Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35(29):1925–31.CrossRefPubMedPubMedCentral
28.
Metadata
Title
Using Resistin, glucose, age and BMI to predict the presence of breast cancer
Authors
Miguel Patrício
José Pereira
Joana Crisóstomo
Paulo Matafome
Manuel Gomes
Raquel Seiça
Francisco Caramelo
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3877-1

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine